Home Blog of Signal Transduction Apoptosis IAP

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

IAP

The expanding role of IAP antagonists for the treatment of head and neck cancer

225 views | Nov 07 2023

IAP antagonists, also known as SMAC mimetics, have shown promising results in preclinical and clinical studies as potential anti-cancer therapeutics for head and neck squamous cell carcinomas (HNSCC), particularly when combined with radiation therapy. [Read the Full Post]

Abrogation of Cellular Senescence Induced by Temozolomide in Glioblastoma Cells: Search for Senolytics

185 views | Jun 17 2023

Targeting senescent cells with senolytic drugs, such as ABT-737, navitoclax, chloroquine, ATMi, ATRi, BV-6, PX-866, fisetin, and artesunate, may improve the outcome of glioblastoma therapy by preventing recurrences and reducing tumor inflammation. [Read the Full Post]

Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic Cells

133 views | Jun 04 2023

Researchers have identified AZD5582 as a compound that enhances dendritic cell cross-presentation of tumor antigens, leading to an increased frequency of systemic tumor antigen-specific CD8+ T cells, which could improve the clinical benefit of immune checkpoint blockade in patients who are unlikely to respond. [Read the Full Post]

Apoptosis or Antiapoptosis? Interrupted Regulated Cell Death of Host Cells by Ascovirus Infection In Vitro

88 views | May 21 2023

This study investigates the antiapoptotic capacity of ascovirus-infected insect cells and their biochemical characteristics during different stages of infection. [Read the Full Post]

SMAC Mimetics Synergistically Cooperate with HDAC Inhibitors Enhancing TNF-α Autocrine Signaling

174 views | May 18 2023

The combination of SMAC mimetics and HDAC inhibitors shows remarkable synergy in suppressing IAP proteins and restoring apoptotic pathways, providing a potential therapeutic strategy for recurrent ovarian cancer. [Read the Full Post]

Celastrol inhibits necroptosis by attenuating the RIPK1/RIPK3/MLKL pathway and confers protection against acute pancreatitis in mice

337 views | May 18 2023

Celastrol has been found to inhibit necroptosis by attenuating the phosphorylation of RIPK1, RIPK3, and MLKL and mitochondrial dysfunction in in vitro models, and in a mouse model of acute pancreatitis, it significantly reduced the severity of the disease and decreased the phosphorylation of MLKL in pancreatic tissues. [Read the Full Post]

Lipopolysaccharide sensitizes the therapeutic response of breast cancer to IAP antagonist

208 views | Apr 03 2023

The study shows that LPS enhances the therapeutic response of IAP antagonists in treating triple-negative and ER+ breast cancer by inducing rapid apoptosis of cancer cells through TLR4- and MyD88-mediated production of TNFα, and suggests that antibiotics that can reduce microbiota-derived LPS should not be used together with an IAP antagonist for cancer therapy. [Read the Full Post]

Drug Repositioning Identifies Six Drug Candidates for Systemic Autoimmune Diseases by Integrative Analyses of Transcriptomes from Scleroderma, Systemic Lupus Erythematosus, and Sjogren's Syndrome

330 views | Jan 25 2023

Elif Kubat Oktem et al. provided new insights and opens up new possibilities on both pathogenesis and treatment of systemic ADs through drug repositioning. [Read the Full Post]

Remarkable Synergy When Combining EZH2 Inhibitors with YM155 Is H3K27me3-Independent

143 views | Jan 25 2023

Jun Yang et al. identified a 27-gene module that was highly expressed in solid tumors, encoding actionable targets including EZH2 and BIRC5. [Read the Full Post]

RB loss determines selective resistance and novel vulnerabilities in ER-positive breast cancer models

193 views | Jul 27 2022

Vishnu Kumarasamy et al. demonstrated the highly selective use of birinapant based combinations for the treatment of RB-deficient tumors. [Read the Full Post]